Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
Jitka Smetanová, Zuzana Střížová, Anna Šedivá, Tomáš Milota, Rudolf Horváth
Topics & Concepts
SecukinumabAdalimumabMedicineImmune systemCoronavirus disease 2019 (COVID-19)ImmunologyVirologyTumor necrosis factor alphaArthritisInternal medicineInfectious disease (medical specialty)DiseasePsoriatic arthritisRheumatoid Arthritis Research and TherapiesSARS-CoV-2 and COVID-19 ResearchAutoimmune and Inflammatory Disorders Research